© 2005 Oxford University Press
ARTICLE |
Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case–Control Study
For the British Tamoxifen Second Cancer Study Group
Affiliation of authors: Section of Epidemiology, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Correspondence to: Professor Anthony J. Swerdlow, DSc, Section of Epidemiology, Brookes Lawley Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK (e-mail: anthony.swerdlow{at}icr.ac.uk).
Background: Tamoxifen treatment of breast cancer is associated with an increased risk of endometrial cancer, but tamoxifen-related risks of endometrial cancer are unclear in premenopausal women, in long-term users of tamoxifen, and in women for whom several years have passed since ending treatment. We conducted a case–control study in Britain to investigate these risks. Methods: We compared treatment information on 813 case patients who had endometrial cancer after their diagnosis for breast cancer and 1067 control patients who had breast cancer but not subsequent endometrial cancer. We assessed risk by conditional logistic regression analysis. All statistical tests were two-sided. Results: Overall, tamoxifen treatment, compared with no treatment, was associated with an increased risk of endometrial cancer (odds ratio [OR] = 2.4; 95% confidence interval [CI] = 1.8 to 3.0). Risk increased statistically significantly (Ptrend<.001) with duration of treatment (for 
5 years of treatment compared with no treatment, OR = 3.6, 95% CI = 2.6 to 4.8). As an indication of background levels of treatment, 16% of control patients received 5 years or more of treatment. Risk of endometrial cancer adjusted for treatment duration did not diminish in follow-up to at least 5 years after the last treatment ended. Risk of endometrial cancer was not associated with the daily dose of tamoxifen and was comparable in pre- and postmenopausal women. Ever treatment with tamoxifen was associated with a much greater risk of Mullerian and mesodermal mixed endometrial tumors (OR = 13.5, 95% CI = 4.1 to 44.5) than of adenocarcinoma (OR = 2.1, 95% CI = 1.6 to 2.7) or clear cell and papillary serous tumors (OR = 3.1, 95% CI = 0.8 to 17.9). Conclusions: There is an increasing risk of endometrial cancer associated with longer tamoxifen treatment, extending well beyond 5 years. The increased risk of endometrial cancer associated with tamoxifen treatment should be considered clinically for both premenopausal and postmenopausal women during treatment and for at least 5 years after the last treatment.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. DeMichele, A. B. Troxel, J. A. Berlin, A. L. Weber, G. R. Bunin, E. Turzo, R. Schinnar, D. Burgh, M. Berlin, S. C. Rubin, et al. Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study J. Clin. Oncol., September 1, 2008; 26(25): 4151 - 4159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Kahn Moving Research From Bench to Bedside to Community: There Is Still More to Do J. Clin. Oncol., February 1, 2008; 26(4): 523 - 526. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cuzick, J. F. Forbes, I. Sestak, S. Cawthorn, H. Hamed, K. Holli, and A. Howell Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial J Natl Cancer Inst, February 21, 2007; 99(4): 272 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment Mutagenesis, July 1, 2005; 20(4): 297 - 303. [Abstract] [Full Text] [PDF]
|
|